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ABSTRACT
The incidence of drug-resistant pathogens differs greatly between countries according to differ-
ences in the usage of antibiotics. The purpose of this study was to investigate the phenotypic re-
sistance of 321 methicillin resistance Staphylococcus aureus (MRSA) and 195 methicillin suscepti-
ble S. aureus (MSSA) in a total of 516 S. aureus strains to macrolide, lincosamide, streptogramin B 
(MLS
B
), ketolid, and linezolid. Disk diffusion method was applied to determine MLS
B
 phenotype 
and susceptibility to different antibiotic agents. It was found that 54.6% of the isolates were resist-
ant to erythromycin (ERSA), 48% to clindamycin, 55% to azithromycin, 58.7% to spiramycin, 
34.7% to telithromycin, and 0.4% to quinupristin-dalfopristin, respectively. No strain resistant to 
linezolid was found. The prevalence of constitutive (cMLS
B
), inducible (IMLS
B
), and macrolides 
and type B streptogramins (M/MS
B
) among ERSA isolates (237 MRSA, 45 MSSA) was 69.6 %, 
18.2%, and 12.2 % in MRSA and 28.9%, 40%, and 31.1% in MSSA, respectively. In conclusions, 
the prevalence of cMLS
B
 was predominant in MRSA; while in MSSA strains, iMLS
B
 and M/MS
B
 
phenotype were more higher than cMLS
B
 phenotype resistance. The resistance to quinupristin-
dalfopristin was very low, and linezolid was considered as the most effective antibiotic against all 
S.aureus strains.
Keywords: Staphylococcus aureus, macrolide, lincosamide, streptogramin B, ketolid, linezolid, MLS
B
. 
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Prevalence of phenotypic resistance of Staphylococcus aureus 
isolates to macrolide, lincosamide, streptogramin B, ketolid 
and linezolid antibiotics in Turkey
INTRODUCTION
Macrolides (e.g., erythromycin, azithromycin, 
spiramycin), lincosamides (e.g., clindamycin, lin-
comycin), and streptogramin B (e.g., quinupris-
tin) are groups of antibiotic collectively named 
MLS
B
.1 They are chemically distinct, but have 
similar inhibitory effects on bacterial protein syn-
thesis. MLS
B
, commonly used in treatment of sta-
phylococcal infections,1 and clindamycin is a fre-
quent choice for some staphylococcal infections, 
particularly skin and soft-tissue infections, and it 
is an alternative in the penicillin-allergic patients.2 
The macrolide antibiotic resistance in S. aureus is 
usually caused either by ribosomal modification 
mediated by 23S rRNA methylases encoded by 
erm genes, or by active efflux of the antimicrobial 
agent by an ATP-dependent pump encoded by 
msrA gene. Methylases confer inducible (iMLS
B
) 
or constitutive (cMLS
B
) resistance, while the ef-
flux mechanism affects only macrolides and type 
B streptogramins (M/MS
B
). Other more rare 
macrolide resistance mechanisms include ribos-
omal mutations and antibiotic inactivation by 
specific hydrolases or phosphotransferases.3 Ke-
tolides belong to the MLS
B
 family, and telithro-
mycin is the first commercially available ketolide.4 
Oxazolidinones and specifically linezolid are 
new class of compounds that binds to the 23S 
portion of the 50S ribosomal subunit, prevent-
ing initiation complex formation with activity 
against methicillin-resistant S. aureus (MRSA) 
and vancomycin-resistant Enterococcus spp. 
(VRE).5 Quinupristin-dalfopristin (Synercid, 
30:70 ratio) is the first parenteral streptogramin 
that has recently been licensed for clinical use 
in the United States and Europe for the treat-
ment of infections caused by multidrug resist-
ant and Gram-positive pathogens.6
Quinupristin and dalfopristin enter bacterial 
cells by diffusion and bind to different sites on the 
50S ribosomal subunit, resulting in an irrevers-
ible inhibition of bacterial protein synthesis. The 
combination synergistic effect appears to result 
from the fact that these compounds target early 
and late steps in protein synthesis.7
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Prevalence of MLS
B
, ketolid, and linezolid antibiotics resistance in Staphylococcus aureus strains
In vitro tests show that strains with constitutive 
resistance are resistant to all macrolides, which comprise 
14-(e.g.erythromycin), 15-(e.g.azithromycin), and 16-
membered rings (e.g. spiramycin), lincosamides, and strep-
togramin B, while inducibly-resistant strains are resistant 
only to 14- and 15- membered-ring macrolides.3 The ob-
jective of the present study was to investigate prevalence of 
MLS
B
, ketolid, and linezolid phenotypic resistance in clinical 
S. aureus strains.
MATERIAL AND METHODS
Bacterial strains
Between January 2006 and April 2007, 321 MRSA and 195 
MSSA, a total of 516 S. aureus isolates were obtained from dif-
ferent clinical specimens at Haydarpasa Numune Education 
and Research Hospital in Istanbul, Turkey. The isolates were 
identified according to Gram stain, catalase, and coagulase 
production (Slidex Staph Plus, Biomérieux, France). Dupli-
cate isolates was not included. S. aureus ATCC 25923 was used 
as quality control in susceptibility testing.
Antimicrobial disks
Antimicrobial disks were purchased from Oxoid (Hemakim, 
Istanbul, Turkey).
Determination of antimicrobial susceptibility test 
and MLS
B
 phenotype resistance patterns 
MLS
B
 phenotype resistance pattern was determined 
according to the method advised by Clinical and Laboratory 
Standards Institute (CLSI).8 Briefly, an overnight culture of 
each isolate was adjusted to 0.5 McFarland (108 cf/mL) and 
spread on unsupplemented Mueller-Hinton agar (HIME-
DIA, Himedia Laboratories, Mumbai , India). The following 
antibiotic disks were applied on an inoculated media: azi-
thromycin (Az-15 μg), spiramycin (Sp 100 μg), telithromy-
cin (Te-15 μg), quinupristin-dalfopristin (Q-D-15 μg), and 
linezolid (Li-30 μg), erythromycin (E-15 μg), and clindamy-
cin (Cl-2 μg) disks were placed by hand to provide distances 
of 15-26 mm from edge to edge. Following incubation for 
16 to 18 hours at 35° C, zone diameters were measured in 
the usual manner; any flattening or blunting of clindamycin 
zone shape (D-shape), indicating iMLS
B
, while resistance to 
both erythromycin and clindamycin indicated cMLS
B
. Lack 
of a D-shaped zone in erythromycin resistant and clindamy-
cin-susceptible isolates were interpreted as M/MS
B
. Due to 
lack of CLSI zone diameters criteria for spiramycin, we used 
the Comite´ de l’Antibiogramme de la Socie´te´ Française de 
Microbiologie recommendation of zone diameters ≥ 24 mm 
as susceptible, and < 19 mm as resistance.9
RESULTS
Of the 516 isolates, 237 MRSA and 45 MSSA, a total of 
282 (54.6%) S. aureus isolates were found to be resistant 
to erythromycin (ERSA) and the rest was susceptible to 
erythromycin (ESSA), 248 (48%) isolates were resistant to 
clindamycin, 284 (55%) to azithromycin, 303 (58.7%) to 
spiramycin, 179 (34.7%) to telithromycin, and two (0.4%) 
strains to quinupristin-dalfopristin. No strain resistant to 
linezolid was found. As for phenotypic resistance of ERSA 
isolates, the rate of cMLS
B
, iMLS
B
, and M/MS in 282 ERSA 
strains was 178 (63%) cMLS
B
, 61 (22%) iMLS
B
, and 43 (15%) 
M/MS
B
, respectivley. The distribution of cMLS
B
, iMLS
B
, 
and M/MS
B
 in ERSA-MRSA isolates was 69.6 %, 18.2%, 
and 12.2 %; and in ERSA-MSSA isolates it was 28.9%, 40%, 
and 31.1%, respectively, which showed a predominance of 
cMLS
B
 in MRSA, while iMLS
B
 and M/MS
B
 phenotypic re-
sistance patterns were higher in MSSA isolates (Table 1). 
DISCUSSION
This study was conducted at the largest educational hospi-
tal in Istanbul-Turkey to investigate the prevalence of MLS
B
, 
ketolid, and linezolid in 516 S. aureus isolates. The preva-
lence of ERSA in Turkish isolates was found to be higher 
(54.6%) than those obtained (39%) in a study perfomed 
by the neighbours of Turkey with the participation of 20 
European university hospitals.10 This differance is more 
likely attributed to the high proportion of MRSA (62.2%) 
in our S .aureus isolates compaed to that of the European 
study (22%). However, they also reported10 higher rate of 
cMLS
B
 in MRSA (93%) and MSSA (44%) than we obtained 
in MRSA (69.6%) or in MSSA isolates (28.9%). Aktas et al.11 
conducted a study at the University hospital in Turkey on 
only 22 MRSA and found that 63%, 18%, and 18% of the 
isolates exhibited cMLS
B
, iMLS
B
, and M/MS
B
, respectively. 
Spiliopoulou et al.12 have mentioned in a study on ERSA 
strains that only 5.3% of MRSA isolates expressed iMLS
B 
and the rest displayed cMLS
B
, while in MSSA, 78.3% were 
iMLS
B
 and 21.7% were M/MS
B
, similar with our finding in 
which the percentage of M/MS
B
 (31.1%) in MSSA was two-
fold higher (12.2%) than in MRSA. A study of Janapatla et 
al.13 from Taiwan reported that iMLS
B
 was predominant in 
MSSA (8%) than in MRSA (4%). Otsuka et al.14 have also re-
ported that 61.3% of the Japanese MRSA isolates expressed 
cMLS
B
 and 94% of the MSSA isolates displayed iMLS
B
. 
A retrospective study conducted by Modak et al.15 on 13,946 
S. aureus strains collected between 1994-2005 revealed a 
stable incidence of cMLS
B
 strains, but also a significant in-
crease in the incidence of isolates that were susceptible to 
clindamycin and resistant to erythromycin, and in iMLS
B
. 
They attributed this high incidence to the increased use of 
macrolides and clindamycin during the same period. Me-
rino-Díaz et al.16 reported that the rate of iMLS
B
 resistance 
was significantly higher in S. aureus (5.2%) than the rate of 
cMLS
B
 (1.7%) in cutaneous strains from Spain. On the other 
hand, 41.5% of the ESSA isolates (44.7% of MSSA and 35.7% 
of MRSA) were highly resistant to spiramycin, in contrast 
to the low resistance rate to clindamycin (4%) and azithro-
mycin (1%). The ribosomal mutations and antibiotic inac-
13Braz J Infect Dis 2010;14(1):11-14
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tivation are the mechanisms that might play a role in the last 
resistance of ESSA and differ from MLS
B
.3 Only 0.4% of the S. 
aureus isolates were resistant to quinupristin-dalfopristin and 
this agent was effective in all of the examined isolates. There 
was concern regarding the use of streptogramin antibiotic 
(virginiamycin) as a feed additive in the animal husbandry 
and development of cross-resistance against this antibiotic.17 
Although the first resistance to linezolid was reported in 2001 
due to mutations in the 23S rRNA,18 we did not detect any 
resistance or even decreased susceptibility to this antibiotic, 
and most reports have shown that the resistance rate to this 
agent is still low.18-20 Our study and review of the studies re-
lated to macrolides resistance in S. aureus demonstrated that 
methicillin resistance leads physicians to use different mac-
rolides, mainly eryhromycin, azithromycin, and spiramycin or 
lincosamides, such as clindamycin and lincomycin which facili-
tate development of different MLS
B 
phenotypic patterns, and 
which mostly end with resistance to macrolides, lincosamide, 
streptogramin B, and ketolid (cMLS
B
). We believe that this is 
the reason behind the increased prevalence of cMLS
B
 in geo-
graphical area with high prevalence of MRSA, and vice versa. 
Our study showed that the prevalence of MLS
B
 in 
Turkish S. aureus isolates was high and that the predominant 
phenotype was cMLS
B
 in MRSA and iMLS
B
 and M/MS
B
 in 
MSSA isolates, which is in agreement with reports of most 
countries. Linezolid and quinupristin-dalfopristin were very 
effective and promising. The accurate use of these new agents 
might avoid treatment failure especially in macrolid-resistant 
S. aureus infections.
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